"A Phase 1, double- blinded, randomised, placebo-controlled...

"A Phase 1, double- blinded, randomised, placebo-controlled dose-escalation study to assess safety, tolerability and pharmacokinetics of NOX66 in healthy subjects when administered over 3 cohorts as a single NOX66 dose of 400 mg, 600 mg, 1200 mg in comparison to single oral doses administered over 6 Cohorts of 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 600 mg idronoxil."

Sounds like data to prove one thing that the suppository has superior pharmacokinetics than the oral.